📰 ET Markets 🟢 BULLISH 🕒 12 Oct 2026, 03:25 PM IST

Smallcaps have surged 2.3x since April 2023. Why Vikas Khemani still sees India’s next multibaggers here

⚡ Instant Key Takeaways (TL;DR)

🎯

Core Development: Smallcaps have surged 2.3x since April 2023. Why Vikas Khemani still sees India’s next multibaggers here

📊

Market & Financial Impact: Smallcaps have surged 2.3 times since April 2023, but Carnelian Capital founder Vikas Khemani believes the segment still offers India’s next multibaggers. Despite elevated valuations, stronger earnings growth, greater domestic exposure, and a wider pool of high-growth businesses could create opportunities for investors who focus on stock selection and management quality.

💡

Actionable Insight: 🟢 Bullish Trigger: Positive business expansion or earnings beat may attract institutional and retail buying.

Smallcaps are expected to grow profits at a 22% annual rate between FY26 and FY28, compared with 16% for large caps.

Top Trending Stocks: SBI Share Price, Axis Bank Share Price, HDFC Bank Share Price, Infosys Share Price, Wipro Share Price, NTPC Share Price

Brinjal, buffalo, bacteria: Inside India’s pay-for-nature system

Homebuyers wait as NCLT panel picks holes in unfinished Jaypee projects

📰

Official Publisher Attribution: This report is aggregated from Economic Times. ZeroLive provides live aggregation, automated sentiment synthesis, and exchange disclosure monitoring for retail market participants.

Read Original Full Coverage on Economic Times ↗

Smallcaps have surged 2.3x since April 2023. Why Vikas Khemani still sees India’s next multibaggers here

🔥 More Live Market Stories

[BHAGYANGR] Outcome of Board Meeting - Bhagyanagar India Limited

[ICICIAMC] Investor Presentation - ICICI Prudential Asset Management Company Limited

[INDIACEM] Shareholders meeting - The India Cements Limited

[UNITDSPR] Analysts/Institutional Investor Meet/Con. Call Updates - United Spirits Limited

[ANUHPHR] Certificate under SEBI (Depositories and Participants) Regulations, 2018 - Anuh Pharma Limited

[MASTEK] ESOP/ESOS/ESPS - Mastek Limited